Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
Seeking Alpha / 4 hours ago 1 Views
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025
Comments